Abstract:Background: Hypertension is a major cause of death and morbidity worldwide and is increasing in prevalence. The Renin-angiotensin system (RAS) is the most common mechanism involved in the pathophysiology of hypertension. Understanding the mechanism of the pathophysiologic processes will help direct potential therapeutic strategies to treat hypertension and improve cardiac function. Recently, a novel drug LCZ696 containing both an angiotensin receptor blocker valsartan and a neprilysin inhibitor (AHU377) has shown a promising effect on the treatment of hypertension. However, the effects of LCZ696 on the expression of main components of RAS, namely, angiotensin-converting enzyme (ACE), angiotensin-converting enzyme 2 (ACE2), angiotensin II type 1 receptor (AT1 R), angiotensin II type 2 receptor (AT2 R), and angiotensin (1-7) receptor/Mas receptor (MasR) remain unclear. The aim of the present study was to evaluate the effects of LCZ696 on the protective arms of RAS in the cardiac tissue when compared with valsartan under the equal inhibition of AT1 R. We hypothesized that the superior effects of LCZ696 may contribute to its greater effect on the RAS than valsartan. Materials and methods: Sixteen-week-old female spontaneously hypertensive rats (SHRs) were used in this study. Wistar-Kyoto (WKY) rats were used as controls. All rats were randomly divided into LCZ696 (n = 10), valsartan (n = 10), SHR (n = 10), and WKY (n = 10) groups under a 12-hour dark and 12-hour light cycle and provided with regular chow diet and water. The tail-cuff method was performed to measure blood pressure. Cardiac function was assessed by echocardiography. Results: The blood pressure value was lower in LCZ696 than valsartan in SHR after 12 weeks of treatment. Further, LCZ696 inhibits the ACE and AT1 R protein expression in the cardiac of SHR and significantly upregulate the protective axis of RAS components, including ACE2, MasR, and AT2 R. Left ventricular AT2 R messenger RNA (mRNA) expression was higher in the LCZ696+SHR group compared with valsartan. In addition, real-time polymerase chain reaction analysis revealed that LCZ696 enhanced the mRNA expression of antihypertensive components AT2 R, ACE2, and MasR and decreased the expression of AT1 R. However, only AT2 R and ACE2 mRNA expressions have a statistical difference between the LCZ696 and valsartan groups. No difference was observed in the mRNA expression of ACE and MasR. The stronger positive signal of transforming growth factor β in the left ventricle was inhibited in each administrated group compared with SHR groups. Conclusions: LCZ696 ameliorates the vasoconstrictor axis of the RAS AT1 R and stimulate the protective arm effectors, ACE2 and AT2 R, as well as reverses the compensatory upregulation of neuronal nitric oxide synthase and endothelial nitric oxide synthase in SHR. These findings suggest the mechanistic insight of the cardiac-protective and greater hypotensive effects of LCZ696.

Regulation of Angiotensin-(1–7) and Angiotensin II Type 1 Receptor by Telmisartan and Losartan in Adriamycin-Induced Rat Heart Failure

Losartan Reduced Connexin43 Expression in Left Ventricular Myocardium of Spontaneously Hypertensive Rats

Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction

Protection of renal impairment by angiotensin II type 1 receptor blocker in rats with post-infarction heart failure.

Apoptosis, Myocardial Fibrosis and Angiotensin Ii in the Left Ventricle of Hypertensive Rats Treated with Fosinopril or Losartan

Telmisartan Attenuates Diabetic Nephropathy Progression by Inhibiting the Dimerization of Angiotensin Type-1 Receptor and Adiponectin Receptor-1.

Effect of Losartan and Captopril on Expression of Cardiac Angiotensin II AT1 Receptor Mrna in Rats Following Myocardial Infarction.

The Effects of Different Angiotensin II Type 1 Receptor Blockers on the Regulation of the ACE-AngII-AT1 and ACE2-Ang(1–7)-Mas Axes in Pressure Overload-Induced Cardiac Remodeling in Male Mice

Angiotensin Ii Type 2 Receptor Correlates with Therapeutic Effects of Losartan in Rats with Adjuvant-Induced Arthritis

Effects of Telmisartan on the Expression of Myocardial Β - Myosin Heavy Chain in Rats with Renovascular Hypertension

Telmisartan attenuates aortic hypertrophy in hypertensive rats by the modulation of ACE2 and profilin-1 expression

Effect of telmisartan on the relation between perirenal adipose and blood pressure in high-fat diet-induced obese rats

Effects of Angiotensin 1-7 and Mas Receptor Agonist on Renal System in a Rat Model of Heart Failure

Reduction of asymmetric dimethylarginine involved in the cardioprotective effect of losartan in spontaneously hypertensive rats.

The Effects of Telmisartan on Congestive Heart Failure and Its Influence to AngiotensinⅡand Natriuretic Peptide

Variation of Serum Angiopoietin-2 in Renovascular Hypertensive Rats and Therapeutic Effect of Telmisartan

AHU377+Valsartan (LCZ696) Modulates Renin-Angiotensin System (RAS) in the Cardiac of Female Spontaneously Hypertensive Rats Compared With Valsartan

Telmisartan ameliorates cardiac fibrosis and diastolic function in cardiorenal heart failure with preserved ejection fraction

Comparison of Angiotensin II Type 1-Receptor Blockers to Regress Pressure Overload-Induced Cardiac Hypertrophy in Mice.

Reversal of subcellular remodelling by losartan in heart failure due to myocardial infarction

TLR4/MyD88/NF-κB Signaling and PPAR-γ Within the Paraventricular Nucleus Are Involved in the Effects of Telmisartan in Hypertension.